Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | PKLR | P30613 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | PTGDR | Q13258 | 7/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12209246 | 0.86 | HTT (0.66) | DHCR7ALDH1A1PKMNPC1PKLR | |
| SCHEMBL17100765 | 0.85 | MAPT (0.58) | MAPTALDH1A1PKMNPC1PKLR | |
| SCHEMBL16788114 | 0.84 | HTT (0.69) | DHCR7ALDH1A1PKMNPC1PKLR | |
| SCHEMBL1352340 | 0.83 | PKM (0.77) | MAPTALDH1A1PKMNPC1PKLR | |
| SCHEMBL19348522 | 0.82 | DHCR7 (0.59) | DHCR7PKMNPC1PKLRRAB9A | |
| SCHEMBL29483645 | 0.82 | LMNA (0.69) | DHCR7ALDH1A1HTTKMT2A | |
| Hydrochloric Acid SCHEMBL3245890 | 0.81 | PKM (0.75) | MAPTALDH1A1PKMNPC1PKLR | |
| SCHEMBL9976064 | 0.80 | MAPT (0.68) | MAPTALDH1A1PKMKMT2A | |
| SCHEMBL1106916 | 0.79 | DHCR7 (0.67) | DHCR7MAPTPKMNPC1PKLR | |
| SCHEMBL16026448 | 0.79 | GAA (0.73) | MAPTALDH1A1PKML3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1939175-B1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-9440938-B2 | Sulfonamide derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2016-09-13 | — | — | US | disclosed |
| US-9440938-B2 | Sulfonamide derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2016-09-13 | — | — | US | disclosed |
| US-9440938-B2 | Sulfonamide derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2016-09-13 | — | — | US | disclosed |
| US-20150158833-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO (JP) | 2015-06-11 | — | — | US | disclosed |
| US-20150158833-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO (JP) | 2015-06-11 | — | — | US | disclosed |
| US-20150158833-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO (JP) | 2015-06-11 | — | — | US | disclosed |
| CN-103265501-B | Method for producing N-phenyl-N'-phenylsulfonylpiperazine derivative | SHIONOGI & CO | 2015-06-03 | — | — | CN | disclosed |
| US-20150057447-A1 | METHOD OF PRODUCING N-PHENYL-N'-PHENYLSULFONYL PIPERAZINE DERIVATIVE AND INTERMEDIATE THEREOF | SHIONOGI & CO., LTD. (JP) | 2015-02-26 | — | — | US | disclosed |
| US-20150057447-A1 | METHOD OF PRODUCING N-PHENYL-N'-PHENYLSULFONYL PIPERAZINE DERIVATIVE AND INTERMEDIATE THEREOF | SHIONOGI & CO., LTD. (JP) | 2015-02-26 | — | — | US | disclosed |
| EP-2832729-A1 | N-PHENYL-N'-PHENYLSULFONYLPIPERAZINE DERIVATIVE AND METHOD FOR PRODUCING INTERMEDIATE FOR SAME | Shionogi & Co., Ltd. (JP) | 2015-02-04 | — | — | EP | disclosed |
| CN-104321314-A | N-phenyl-n'-phenylsulfonylpiperazine derivative and method for producing intermediate for same | SHIONOGI & CO | 2015-01-28 | — | — | CN | disclosed |
| CN-103265501-A | Method for producing N-phenyl-N'-phenylsulfonylpiperazine derivative | SHIONOGI & CO | 2013-08-28 | — | — | CN | disclosed |
| US-8153793-B2 | Sulfonamide derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-8153793-B2 | Sulfonamide derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-8153793-B2 | Sulfonamide derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| EP-2407453-A1 | PGD2 receptor antagonist | Shionogi & Co., Ltd. (JP) | 2012-01-18 | — | — | EP | disclosed |
| EP-2407459-A1 | Synthetic intermediate in the production of a sulfonamide derivative having PGD2 receptor antagonistic activity | Shionogi & Co., Ltd. (JP) | 2012-01-18 | — | — | EP | disclosed |
| CN-101679267-A | Process for producing N-phenyl-N' -benzenesulfonylpiperazine derivative | SHIONOGI & CO | 2010-03-24 | — | — | CN | disclosed |
| EP-1939175-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | Shionogi&Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158833-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | PTGDR, PTGDR2, CNR2 | DHCR7 2162/4885MAPT 4835/4885ALDH1A1 1440/4885 |
| US-20150057447-A1 | METHOD OF PRODUCING N-PHENYL-N'-PHENYLSULFONYL PIPERAZINE DERIVATIVE AND INTERMEDIATE THEREOF | REN, JAK2, XDH | DHCR7 1049/4885MAPT 3843/4885ALDH1A1 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.